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Background: HuR is an RNA-binding protein that post-transcriptionally modulates the expressions of various target
genes implicated in carcinogenesis, such as CCNA2 encoding cyclin A. No prior study attempted to evaluate the
significance of HuR expression in a large cohort with upper urinary tract urothelial carcinomas (UTUCs).
Methods: In total, 340 cases of primary localized UTUC without previous or concordant bladder carcinoma were
selected. All of these patients received ureterectomy or radical nephroureterectomy with curative intents.
Pathological slides were reviewed, and clinical findings were collected. Immunostaining for HuR and cyclin A was
performed and evaluated by using H-score. The results of cytoplasmic HuR and nuclear cyclin A expressions were
correlated with disease-specific survival (DSS), metastasis-free survival (MeFS), urinary bladder recurrence-free survival
(UBRFS), and various clinicopathological factors.
Results: HuR cytoplasmic expression was significantly related to the pT status, lymph node metastasis, a higher
histological grade, the pattern of invasion, vascular and perineurial invasion, and cyclin A expression (p = 0.005).
Importantly, HuR cytoplasmic expression was strongly associated with a worse DSS (p < 0.0001), MeFS (p < 0.0001),
and UBRFS (p = 0.0370) in the univariate analysis, and the first two results remained independently predictive of
adverse outcomes (p = 0.038, relative risk [RR] = 1.996 for DSS; p = 0.027, RR = 1.880 for MeFS). Cyclin A nuclear
expression was associated with a poor DSS (p = 0.0035) and MeFS (p = 0.0015) in the univariate analysis but was not
prognosticatory in the multivariate analyses. High-risk patients (pT3 or pT4 with/without nodal metastasis) with high
HuR cytoplasmic expression had better DSS if adjuvant chemotherapy was performed (p = 0.015).
Conclusions: HuR cytoplasmic expression was correlated with adverse phenotypes and cyclin A overexpression and
also independently predictive of worse DSS and MeFS, suggesting its roles in tumorigenesis or carcinogenesis and
potentiality as a prognostic marker of UTUC. High HuR cytoplasmic expression might identify patients more likely to
be beneficial for adjuvant chemotherapy.
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Urothelial carcinomas are the most common malignancy
of the urinary tract and are derived from the urothelium
of the upper urinary tract (renal pelvis and ureter) or
lower urinary tract (urinary bladder). Upper urinary tract
urothelial carcinomas (UTUCs), in contrast with urinary
bladder urothelial carcinomas, are relatively rare, account-
ing for 2%~ 8% of urothelial carcinomas [1]. A previous
report disclosed that the ratio of incidences of urothelial
carcinoma in the renal pelvis, ureter, and urinary bladder
was approximately 3:1:51 [2]. However, the prevalence of
UTUC is higher in Taiwan, and the ratio was 1:2.08:6.72
in a single institution study in Taiwan that included 535
cases [3]. Due to unknown reasons, the tumor stage of
UTUC is high when discovered, which leads to an overall





Age (years) <65 138
≥65 202
Tumor side Right 177
Left 154
Bilateral 9
Tumor location Renal pelvis 141
Ureter 150
Renal pelvis and ureter 49
Multifocality Single 278
Multifocal 62
Primary tumor (T) Ta ~ T1 181
T2 ~ T4 159
Nodal metastasis Negative (N0) 312
Positive (N1 ~ N2) 28
Histological grade Low grade 56
High grade 284
Pattern of invasion Non-invasive/Nodular 200
Trabecular 58
Infiltrative 82
Vascular invasion Absent 234
Present 106
Perineurial invasion Absent 321
Present 19
Mitotic rate (per 10 high power fields) <10 173
≥10 167
Cyclin A expression Low 164
High 176
† Cyto. Exp., cytoplasmic expression. * Statistically significant.various prognosticatory factors have been identified, in-
cluding the tumor stage, lymph node status, growth pat-
tern, tumor necrosis, and lymphovascular invasion. Many
molecular markers, such as cadherin-1, hypoxia-inducible
factor (HIF)-1α, and telomerase RNA, were also found to
independently be associated with tumor recurrence and
poor survival [5,6].
Cyclin A is important in regulating cell cycles, including
playing roles in initiating DNA replication in the S phase
and preventing other cyclins from degrading. Expressions
of cyclins are strictly regulated, and degradation of cyclin A
in a timely manner is mandatory for the cell cycle to enter
metaphase [7]. Overexpression of cyclin A and dysregula-
tion of CDK-cyclin complexes promote tumor cell growth
[8]. Cyclin A is also associated with high proliferative activ-
ity in various carcinomas, including breast cancer, lungd other important clinicopathological parameters
HuR Cyto. Exp.† p value Cyclin A Exp. p value
Low High Low High
93 89 0.664 85 95 0.384
77 81 83 75
72 66 0.508 75 63 0.185
98 104 95 107
96 81 0.201 89 88 0.931
71 83 76 78
3 6 5 4
76 65 0.374 66 75 0.607
73 77 78 72
21 28 26 23
143 135 0.261 140 138 0.779
27 35 30 32
109 72 <0.001* 104 77 0.003*
61 98 66 93
166 146 <0.001* 159 153 0.237
4 24 11 17
37 19 0.008* 39 17 0.001*
133 151 131 151
112 88 0.030* 108 92 0.191
24 34 27 31
34 48 35 47
126 108 0.035* 124 110 0.101
44 62 46 60
166 155 0.009* 162 159 0.479
4 15 8 11
89 84 0.588 103 70 <0.001*
81 86 67 100
95 69 0.005* - - -
75 101 - -
Figure 1 Histology and immunohistochemistry (HuR and cyclin A) of upper urinary tract urothelial carcinomas. Representative
hematoxylin-eosin-stained sections of a low-stage urothelial carcinoma (A) and a high-stage, infiltrating urothelial carcinoma (B) which
respectively demonstrated low (C, E) and high (D, F) cytoplasmic HuR and nuclear cyclin A immunoexpressions.
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Furihata et al. demonstrated that overexpression of cyclin
A in UTUC is associated with poor cancer-specific sur-
vival, the tumor grade, and the tumor growth pattern [10].
HuR, a member of the embryonic lethal abnormal vision
(ELAV) protein family, is a turnover- and translation-
regulatory RNA-binding protein (TTR-RBP) that regulatesthe translation and stability of cytoplasmic messenger (m)
RNA [11]. HuR was found to be upregulated in almost all
malignancies tested, including carcinomas originating in
the breast, colon, stomach, pancreas, esophagus, prostate,
lung, thyroid, etc [12]. It binds directly to the U- and AU-
rich elements in the 3’-untranslated region (UTR) of most
target mRNAs, which are termed AREs, or the 5’UTR of











p value No. of
events




Gender Male 158 28 0.8286 32 0.7904 43 0.0369*
Female 182 33 38 36
Age (years) <65 138 26 0.9943 30 0.8470 34 0.5107
≥65 202 35 40 45
Tumor side Right 177 34 0.7366 38 0.3074 44 0.6047
Left 154 26 32 32
Bilateral 9 1 0 3
Tumor location Renal pelvis 141 24 0.0079* 31 0.0659 33 0.1723
Ureter 150 22 25 32
Renal pelvis and
ureter
49 15 14 14
Multifocality Single 273 48 0.0026* 52 0.0127* 64 0.1861
Multifocal 62 18 18 15
Primary tumor (T) Ta ~ T1 181 11 <0.0001* 19 <0.0001* 43 0.2688
T2 ~ T4 159 50 51 36
Nodal metastasis Negative (N0) 312 42 <0.0001* 55 <0.0001* 73 0.1422
Positive (N1 ~ N2) 28 19 15 6
Histological grade Low grade 56 4 0.0215* 3 0.0027* 14 0.0056*
High grade 284 57 67 65
Pattern of invasion Non-invasive/nodular 200 19 <0.0001* 27 <0.0001* 50 0.5398
Trabecular 58 12 13 14
Infiltrative 82 30 30 15
Vascular invasion Absent 234 24 <0.0001* 26 <0.0001* 55 0.1770
Present 106 37 44 24
Perineurial invasion Absent 321 50 <0.0001* 61 <0.0001* 75 0.2169
Present 19 11 9 4
Mitotic rate (per 10 high power
fields)
<10 173 27 0.1607 30 0.0823 43 0.9031
≥10 167 34 40 36
Adjuvant chemotherapy Not performed 311 54 0.4084 61 0.2151 70 0.2740
Performed 29 7 9 9
HuR cytoplasmic expression Low 170 13 <0.0001* 19 <0.0001* 33 0.0370*
High 170 48 51 46
Cyclin A expression Low 170 19 0.0035* 22 0.0015* 36 0.3784
High 170 42 48 43
* Statistically significant.
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nuclei, but translocation to the cytoplasm is necessary for
its regulation upon the expression of target mRNAs. HuR
can stabilize many target mRNAs, including those encod-
ing proteins that take part in tumorigenesis or carcino-
genesis [13]. Furthermore, translation of several target
mRNAs, including cyclin A2, can be upregulated by HuR,
although the exact mechanism is still unclear.Many studies showed that HuR is a prognostic factor in
various carcinomas, such as colorectal adenocarcinoma,
breast carcinoma, ovarian carcinoma, etc [14-16]. HuR
stabilizes the mRNA of cyclin A2 and increases its transla-
tion. Previous studies showed that it plays a critical role in
increasing the proliferative activity of colorectal carcin-
oma, gastric adenocarcinoma, and oral cancer [17-19].
However, correlations of HuR with biologically and
Figure 2 (See legend on next page.)
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Figure 2 Kaplan-Meier plots of disease-specific survival and metastasis-free survival of upper urinary tract urothelial carcinomas.
Kaplan-Meier plots show that the pT stage, nodal status, perineurial invasion, high HuR expression, and high cyclin A expression conferred
significant prognostic impacts on both disease-specific survival (A, C, E, G, I) and metastasis-free survival (B, D, F, H, J).
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unknown.
In this study, by applying an immunohistochemical
study to our well-characterized case collection, we evalu-
ated the association of HuR overexpression with clinico-
pathological parameters and survival of UTUC patients.
Methods
Patients and tumor materials
For the immunohistochemical study and survival analysis,
we retrieved data on 340 consecutive patients with
primary UTUC, who had received surgical resection with
curative intent (ureterectomy, n = 10; nephroureterectomy,
n = 330), from the archives of Chi-Mei Medical Center
(Tainan, Taiwan) between 1996 and 2004. Patients who
underwent palliative resection and those with a history of
previous and/or concurrent urinary bladder cancer were
excluded. Patients with suspicion of lymph node metastasis
received regional lymph node dissection. Cisplatin-based
post-operative adjuvant chemotherapy was performed in
29 out of the 106 patients who had pT3 or pT4 disease or
with nodal involvement. The criteria for the clinicopatho-
logical evaluation were essentially identical to those
described in our previous work [20]. This retrospective
clinical and immunohistochemical studies were approved
by the institutional review board (IRB971006) of Chi-Mei
Medical Center.
Immunohistochemistry for HuR and cyclin A
After preparing and being heated for antigen retrieval as
previously described, tissue sections were incubated
with primary antibodies against HuR (1:100; Zymed
Laboratories, South San Francisco, CA) and cyclin A
(6E6, 1:50; Novocastra, Newcastle, UK) for 1 h, followed
by antibody detection using a ChemMate EnVision kit
(K5001; DAKO, Glostrup, Denmark). Breast carcinoma
tissue with known HuR expression in the cytoplasm and
cyclin A in nuclei was used as the positive control
throughout. Incubation without the primary antibodies
was used as the negative control.
Interpretation and scoring of HuR and cyclin A
The immunohistochemical slides were independently
interpreted by two pathologists (Y-CW and H-YH), who
were blinded to the clinical and pathological results. The
cytoplasmic expression of HuR and nuclear labeling of cyc-
lin A in the UTUC were assessed using a combination of
the percentage and intensity of positively stained tumor
cells to generate a histological score (H-score) [21,22]. TheH-score was calculated using the following equation:
H-score =
P
Pi (i + 1), where i is the intensity score
(which ranged 0 ~ 4), and Pi is the percentage of stained
tumor cells at each intensity (which ranged 0% ~ 100%).
This formula produces a score that ranges 100 ~ 500,
where 100 indicates that 100% of tumor cells were nega-
tive and 500 indicates that 100% of tumor cells were
strongly stained (4+).
Follow-up and statistical analyses
Statistical analyses were performed using the SPSS 14.0
(SPSS, Chicago, IL, USA) software package. The follow-up
duration ranged 1 ~ 176 (median, 38) months. Median
H-scores of cytoplasmic HuR and nuclear cyclin A were
used as the cutoff to dichotomize the study cohort,
separating cases into high- and low-expression groups.
Associations of HuR and cyclin A expression with various
clinicopathological variables were evaluated by a Chi-
squared test. The association between HuR and cyclin A
results was also evaluated. The end points of the analysis
for the entire cohort were the disease-specific survival
(DSS), metastasis-free survival (MeFS), and urinary bladder
recurrence-free survival (UBRFS) which were calculated
from the date of the operation on the UTUC until the
presence of disease-related mortality, systemic metastasis
developed, and urinary bladder recurrence occurred, re-
spectively, or the last follow-up appointment. Univariate
survival analyses were performed using Kaplan-Meier
plots, and survival was evaluated by the log-rank test. In
the Cox multivariate regression model, all parameters with
p < 0.1 at the univariate level were entered to compare
their independent prognostic impacts. For all analyses,




The clinicopathological characters of our patients are listed
in Table 1. The patients’ age at diagnosis ranged 34 ~ 87
(median, 68) years. Multifocal tumors were observed in 62
cases. One hundred and forty-one cases (41.5%) had
tumors involving the renal pelvis, 150 (44.1%) involving the
ureter, and 49 (14.4%) involving both locations. The pT
stages of 181 cases were non-invasive (Ta, Figure 1A) or
early invasive (T1), and the other 159 cases were advanced
stages (T2 ~T4). The majority of cases (n = 284, 83%) were
high-grade tumors (Figure 1B). Lymph node involvement
was observed in 28 cases. Most tumors (n = 200) were
non-invasive or had a nodular invasion pattern and
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field, n = 173), while 58 and 82 cases respectively displayed
a trabecular or infiltrative pattern of invasion. In addition,
vascular invasion and perineurial invasion were respectively
observed in 106 and 19 cases, respectively.
Correlations of immunoreactivity of HuR and cyclin A
with parameters in UTUC
HuR nuclear expression was detected in both normal
urothelial cells and UTUCs (Figure 1C, D), but HuR cyto-
plasmic expression was seen in the cancer cells only. The
tumors displayed a wide range of H-scores, from 100 to
480 (median, 240). After dichotomizing the tumors into
low- and high-HuR expression (Figure 1C, D, respectively),
as demonstrated in Table 1, high HuR expression showed a
strong association with increments of the pT status
(p < 0.001), lymph node metastasis (p < 0.001), a higher
histological grade (p = 0.008), infiltrative or trabecular
pattern of invasion (p = 0.030), vascular (p = 0.035) and
perineurial invasion (p = 0.009), and cyclin A expression
(p = 0.005).
For cyclin A nuclear expression (Figure 1E, F), H-scores
ranged from 100 to 380 (median, 140). Similarly, high cyc-
lin A expression (Figure 1F) was significantly linked to
increments in the pT status (p = 0.003), a higher histo-
logical grade (p = 0.001), and frequent mitosis (p < 0.001).Table 3 Multivariate analyses of disease-specific, metastasis-f










Positive vs. negative 5.602 2.912 ~ 10.776 <0.00
Perineurial
invasion
Present vs. absent 3.291 1.522 ~ 7.117 0.002
Multifocality Multifocal vs. single 2.816 1.321 ~ 6.004 0.007
Pattern of
invasion
Infiltrative vs. trabecular vs.
non-invasive/Nodular
1.596 1.090 ~ 2.337 0.016
Histological
grade
High grade vs. low grade 3.751 1.170 ~ 12.024 0.026
HuR Cyto.
Exp.†
High vs. low 1.996 1.039 ~ 3.834 0.038
Vascular
invasion
Present vs. absent 1.549 0.823 ~ 2.913 0.17
Cyclin A
expression
High vs. low 1.632 0.909 ~ 2.932 0.10
Primary
tumor (T)
T2 ~ T4 vs. Ta ~ T1 1.412 0.586 ~ 3.400 0.44
Tumor
location
Both renal pelvis and ureter
vs. one location alone
0.950 0.614 ~ 1.471 0.81
Mitotic rate ≥10 vs. <10/10 hpf - - -
Gender Male vs. female - - -
† Cyto. Exp., cytoplasmic expression. * Statistically significant.Survival analyses
Associations of clinical outcomes with various clinico-
pathological and immunohistochemical parameters in the
univariate analysis are shown in Table 2. Results showed
that a poor DSS was significantly associated with the tumor
location (p = 0.0079), multifocality (p = 0.0026), pT stage
(p < 0.0001, Figure 2A), lymph node metastasis (p < 0.0001,
Figure 2C), histological grade (p = 0.0215), pattern of inva-
sion (p < 0.0001), vascular and perineurial invasion (both p
< 0.0001, Figure 2E), high cytoplasmic HuR expression
(p < 0.0001, Figure 2G), and high nuclear cyclin A expres-
sion (p = 0.0035, Figure 2I). All of these factors, except for
the tumor location, were also strongly correlated with a
worse MeFS in the univariate analysis (Table 2, Figure 2B,
D, F, H, J). For UBRFS, male gender (p = 0.0369,
Figure 2K), higher histological grade (p = 0.0056), and cyto-
plasmic HuR expression (p = 0.0370, Figure 2L) associated
with poor outcome (Table 2).
In the multivariate analysis, as shown in Table 3, lymph
node metastasis (p < 0.001), perineurial invasion
(p = 0.002), multifocality (p = 0.007), the pattern of invasion
(p = 0.016), and a high histological grade (p = 0.026) were
related to a dismal DSS. For MeFS, lymph node metastasis
(p = 0.001), perineurial invasion (p = 0.025), multifocality
(p = 0.024), a high histological grade (p = 0.023), and vascu-
lar invasion (p = 0.002) were correlated with poorree, and urinary bladder recurrence-free survival
















1* 3.174 1.648 ~ 6.115 0.001* - - -
* 2.460 1.120 ~ 5.401 0.025* - - -
* 2.408 1.124 ~ 5.158 0.024* - - -
* 1.307 0.906 ~ 1.885 0.152 - - -
* 4.187 1.221 ~ 14.364 0.023* 2.113 1.173-3.805 0.013*
* 1.880 1.074 ~ 3.291 0.027* 1.398 0.886-2.204 0.150
5 2.872 1.486 ~ 5.550 0.002* - - -
1 1.703 0.994 ~ 2.918 0.053 - - -
2 0.916 0.419 ~ 2.003 0.826 - - -
9 0.786 0.572 ~ 1.340 0.541 - - -
0.849 0.514 ~ 1.402 0.523 - - -
- - - 1.607 1.030-2.507 0.036*
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(p = 0.013) significantly associated with worse UBRFS.
Interestingly, high HuR expression was significantly corre-
lated with a poor DSS (p = 0.038) and MeFS (p = 0.027) but
not UBRFS (p = 0.150). Cyclin A expression did not associ-
ate with all three survival outcome.
Adjuvant chemotherapy did not significantly improve
the DSS, MeFS, and UBRFS when taking all patients into
accounted (Table 2). However, the sub-group analysis for
high-risk patients (pT3 or pT4 or with nodal metastasis
[n = 106]) showed that adjuvant chemotherapy significantly
improved the DSS (p = 0.0228, Figure 3A). Besides, high-
risk patients with high HuR cytoplasmic expression
(n = 78) had better DSS if adjuvant chemotherapy was per-
formed (p = 0.015, Figure 3C). In contrast, the DSS of
high-risk patients with low HuR cytoplasmic expression
did not improved by adjuvant chemotherapy (p = 0.9548,
Figure 3E). The MeFS showed a trend of improvement, in
all high-risk patients (p = 0.0817, Figure 3B) and those
with high HuR cytoplasmic overexpression (p =0.0800,
Figure 3D), but was not statistically significant. Adjuvant
chemotherapy had no effect on the MeFS of high-risk
patients with low HuR patients (p = 0.7523, Figure 3F) and
neither UBRFS of high-risk patients, including those with
high or low HuR expression (p = 0.3178, p = 0.3870,
p = 0.4054, respectively).Discussion
Aberrant expression of cancer-related proteins is an essen-
tial mechanism in developing malignancies. Protein manu-
facture can be modified through post-transcriptional
mechanisms, such as mRNA splicing, transport, storage,
translation, and degradation [23]. TTR-RBPs and noncod-
ing RNA (especially microRNA) are the two main classes
of factors which regulate these processes [24,25].
mRNA-binding proteins regulating various essential
traits of cell biology underlying tumor aggressiveness is
well established. The Hu/ELAV protein family was among
the first RBPs that showed an association with carcinogen-
esis, after Szabo et al. discovered that HuD was a target in
small-cell lung cancer-associated paraneoplastic enceph-
alomyelitis [26]. This family is composed of one ubiquitous
protein (HuR, also known as HuA) and three neuronal
proteins (HuB, HuC, and HuD). As mentioned earlier,
HuR is overexpressed in virtually almost all tested malig-
nancies. It stabilizes and/or upregulates the translation of
many mRNAs of cancer-related proteins. By regulating tar-
get mRNAs of these proteins, HuR expression showed the
ability to enhance tumor cell proliferation, increase cell
survival and local angiogenesis, evade immune recognition,
and promote cancer cell invasion and metastasis [23]. In
this study, we demonstrated the expression status and sub-
cellular localization of HuR proteins in a sufficiently largecohort of UTUC cases. For those cases with immunoreac-
tivity above the median score, HuR cytoplasmic expression
was significantly correlated with poor outcomes and ad-
verse clinicopathological factors, such as a higher histo-
logical grade, an advanced pathological status, the presence
of lymph node metastasis, the pattern of invasion, and vas-
cular/perineurial invasion. These findings suggest that
HuR expression is associated with carcinogenesis of UTUC
and is an important indicator of tumor aggressiveness.
Cyclin A is a crucial component in regulating the cell
cycle. Cyclin A binds CDK2 when a cell enters the S-phase
to stimulate DNA synthesis. Later, it binds CDK1 when a
cell enters the G2 phase to initiate chromosome condensa-
tion and possibly nuclear envelope breakdown. It is
degraded before a cell enters the M-phase. Overexpression
of cyclin A was correlated with a poor prognosis in various
malignancies, including lung cancer, breast cancer, sar-
coma, and melanoma [9]. Our results show that high cyclin
A expression in tumor cell nuclei was correlated with a
high pT stage, a higher histological grade, and frequent
mitoses. Its associations with DSS and MeFS were signifi-
cant in the univariate analysis but not the multivariate ana-
lysis. These findings are comparable with previous
published observations [10]. In addition, increased HuR
cytoplasmic expression was correlated with high cyclin A
nuclear staining, which was also compatible with what was
observed in other cancers [13].
The effect of adjuvant chemotherapy in UTUC is incon-
clusive. Soga et al. showed that adjuvant chemotherapy
with methotrexate, vinblastine, Adriamycin, and Cisplatin
could prevent the intravesicle recurrence. [27] Other re-
search groups established that there was no significant sur-
vival benefit associated with adjuvant chemotherapy.
[28,29] However, our result demonstrated that adjuvant
chemotherapy improved the DSS of the high-risk patients
(pT3 or pT4 or with nodal involvement) in univariate ana-
lysis. Interestingly, we found that the DSS of patients with
high HuR cytoplasmic expression in the tumor cells can be
improved with adjuvant chemotherapy. This suggests that
high HuR cytoplasmic expression might identify a sub-
group of patients more likely to be beneficial by adjuvant
chemotherapy. Such finding is also in line with pancreatic
ductal adenocarcinoma patients. [30] Costantino et al.
showed that modulation of the metabolizing enzyme of
gemcitabine by HuR overexpression can enhanced the sen-
sitivity of pancreatic cancer cells to the drug. [31] Whether
such observation apply on UTUC warrant further studies.
Recently, many molecular markers that are related to cell
proliferation, angiogenesis, and apoptosis were tested in
UTUC tissues. Some of them proved to be prognosticatory.
Snail, Bcl-2, HIF-1a, and metalloproteinases are among
those that were correlated with adverse prognostic factors
and poor survival [5,6]. Interestingly, mRNAs of all these
markers, together with cyclin A, can be stabilized when
Figure 3 Kaplan-Meier plots of disease-specific survival and metastasis-free survival of high-risk upper urinary tract urothelial
carcinomas (pT3 or pT4 or with nodal metastasis) with or without cisplastin-based adjuvant chemotherapy. Kaplan-Meier plots show
high-risk patients who received cisplastin-based adjuvant chemotherapy conferred significant prognostic impacts on disease-specific survival
(DSS) (A). The DSS of patients with HuR high expression in tumor cells was significantly improved by adjuvant chemotherapy (C). The MeFS was
also improved in those with HuR high expression in tumor cells if adjuvant chemotherapy was given but was not statistically significant (B and
D). Adjuvant chemotherapy did not change the DSS and MeFS in the patients with low HuR expression in tumor cells (E and F).
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of Snail and HIF-1a is upregulated by HuR. It seems that
increased expression of HuR in the cytoplasm of UTUC
may stabilize and increase the production of various
cancer-related proteins, and thus promote tumor aggres-
siveness. These may partly explain why HuR but not cyclin
A was correlated with the pattern of invasion, vascular
invasion, perineurial invasion, and nodal metastasis in our
study.
Conclusions
In summary, cytoplasmic HuR expression can be detected
in most UTUCs but not normal urothelium, and was sig-
nificantly associated with adverse clinicopathological fac-
tors. Furthermore, cytoplasmic HuR expression was
positively related to cyclin A expression and can be used as
an independent factor to predict poor DSS and MeFS.
High HuR cytoplasmic expression might identify patients
more likely to be beneficial for adjuvant chemotherapy.
These results suggest that HuR may play an important role
in tumorigenesis of UTUCs and confers an aggressive
phenotype.
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